Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

JAMA network open·2022

Same author

Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study.

Rheumatology (Oxford, England)·2022

Same author

Antiphospholipid syndrome: the burden of inadequate anticoagulation management.

Clinical and experimental rheumatology·2022

Same author

Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual.

Arthritis care & research·2022

Same author

Optimising ANCA-associated vasculitis management and infectious risks during the COVID-19 pandemic.

Clinical and experimental rheumatology·2022

Same author

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry.

RMD open·2022

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Therapeutic apheresis for myositises.

Véronique Le Guern¹, Loïc Guillevin

¹Service de Médecine Interne, Hôpital Cochin, AP-HP, Université de Paris - René-Descartes, 27, rue du faubourg Saint-Jacques, 75689 Paris Cedex 14, France.

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis

|April 21, 2007

Summary

Therapeutic plasma exchange (TPE) may help treat inflammatory myopathies that do not respond to standard treatments. This approach is particularly suggested for acute cases, often alongside immunosuppressive therapies.

Related Experiment Videos

Last Updated: Jul 15, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Area of Science:

Neurology
Immunology
Rheumatology

Background:

Inflammatory myopathies are acquired, treatable muscle disorders.
Dermatomyositis and polymyositis are common forms, often responsive to immunosuppression.
Refractory cases necessitate exploring alternative therapeutic strategies.

Purpose of the Study:

To evaluate the potential role of Therapeutic Plasma Exchange (TPE) in managing refractory inflammatory myopathies.
To explore TPE as an adjunctive therapy for acute and severe inflammatory myopathies.

Main Methods:

Review of existing observations and clinical experience with TPE in autoimmune diseases.
Analysis of TPE's immunomodulatory mechanisms in the context of inflammatory myopathies.
Consideration of TPE in combination with established immunosuppressive and anti-B-lymphocyte treatments.

Main Results:

TPE has a long history of use in autoimmune conditions, with partially understood mechanisms.
Clinical observations suggest TPE may be beneficial for refractory inflammatory myopathies, especially acute forms.
Controlled trial data supporting TPE in this specific context is currently lacking.

Conclusions:

Therapeutic plasma exchange (TPE) shows promise as a treatment option for inflammatory myopathies resistant to conventional therapies.
TPE is preferentially indicated for refractory and acute inflammatory myopathies.
Combination therapy involving TPE, immunosuppression, and/or anti-B-lymphocyte agents may offer enhanced efficacy.